Buerger's disease primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Ahmed Younes (talk | contribs) |
||
| (9 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Buerger's disease}} | {{Buerger's disease}} | ||
{{CMG}} | {{CMG}};{{AE}}{{HM}} | ||
==Overview== | |||
An effective measure for the primary prevention of Buerger's disease is [[smoking cessation]]. This should include complete abstinence without the use of nicotine-containing anti-smoking aids, such as transdermal patches and gum. However, the use of [[bupropion]] and [[varenicline]] for preventing cravings is permissible. | |||
==Primary Prevention== | ==Primary Prevention== | ||
* [[ | *An effective measure for the primary prevention of Buerger's disease is [[smoking cessation]].<ref name="pmid10995867">{{cite journal |vauthors=Olin JW |title=Thromboangiitis obliterans (Buerger's disease) |journal=N. Engl. J. Med. |volume=343 |issue=12 |pages=864–9 |date=September 2000 |pmid=10995867 |doi=10.1056/NEJM200009213431207 |url=}}</ref><ref name="pmid2225420">{{cite journal |vauthors=Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR |title=The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease) |journal=Circulation |volume=82 |issue=5 Suppl |pages=IV3–8 |date=November 1990 |pmid=2225420 |doi= |url=}}</ref><ref name="pmid14718836">{{cite journal |vauthors=Ohta T, Ishioashi H, Hosaka M, Sugimoto I |title=Clinical and social consequences of Buerger disease |journal=J. Vasc. Surg. |volume=39 |issue=1 |pages=176–80 |date=January 2004 |pmid=14718836 |doi=10.1016/j.jvs.2003.08.006 |url=}}</ref> | ||
*This should include complete abstinence without the use of nicotine-containing anti-smoking aids, such as transdermal patches and gum. However, the use of [[bupropion]] and [[varenicline]] for preventing cravings is permissible. | |||
==References== | ==References== | ||
| Line 10: | Line 14: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Cardiovascular diseases]] | [[Category:Cardiovascular diseases]] | ||
[[Category:Angiology]] | [[Category:Angiology]] | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
[[Category:Up-To-Date]] | |||
Latest revision as of 19:42, 1 May 2018
|
Buerger's disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Buerger's disease primary prevention On the Web |
|
American Roentgen Ray Society Images of Buerger's disease primary prevention |
|
Risk calculators and risk factors for Buerger's disease primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Overview
An effective measure for the primary prevention of Buerger's disease is smoking cessation. This should include complete abstinence without the use of nicotine-containing anti-smoking aids, such as transdermal patches and gum. However, the use of bupropion and varenicline for preventing cravings is permissible.
Primary Prevention
- An effective measure for the primary prevention of Buerger's disease is smoking cessation.[1][2][3]
- This should include complete abstinence without the use of nicotine-containing anti-smoking aids, such as transdermal patches and gum. However, the use of bupropion and varenicline for preventing cravings is permissible.
References
- ↑ Olin JW (September 2000). "Thromboangiitis obliterans (Buerger's disease)". N. Engl. J. Med. 343 (12): 864–9. doi:10.1056/NEJM200009213431207. PMID 10995867.
- ↑ Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR (November 1990). "The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease)". Circulation. 82 (5 Suppl): IV3–8. PMID 2225420.
- ↑ Ohta T, Ishioashi H, Hosaka M, Sugimoto I (January 2004). "Clinical and social consequences of Buerger disease". J. Vasc. Surg. 39 (1): 176–80. doi:10.1016/j.jvs.2003.08.006. PMID 14718836.